Promega, Cellectar, Blockchain, & More: This Week’s WI Watchlist

(Page 2 of 2)

culture of entrepreneurship” in the area it serves. Two dozen higher learning institutions are located in the area, and all of them are reportedly part of The Commons. “A collaboration of this magnitude is the only way we will compete in the future economic environment,” Joe Poeschl, one of The Commons’ co-founders, told VentureBeat.

—Arrowhead Pharmaceuticals (NASDAQ: ARWR) shared data from a study involving a drug candidate whose development was canceled last year. The company said it believes the data could augur well for a new compound it has since begun developing to treat chronic hepatitis B virus. Arrowhead is developing the new compound, which is still preclinical, using a new type of RNA interference drug delivery platform the company unveiled in September. Arrowhead is headquartered in Pasadena, CA, but a majority of its employees work from its offices in Wisconsin.

—Madison-based Kiio raised $300,000 in equity funding from a single investor, according to a securities filing. The company develops software and hardware to help patients understand and adhere to exercise programs to rehabilitate (or prevent) injuries. Kiio has now raised nearly $6.8 million from investors since launching in 2011, SEC filings show.

Single PageCurrently on Page: 1 2 previous page

Jeff Buchanan is the editor of Xconomy Seattle. Email: jbuchanan@xconomy.com Follow @_jeffbuchanan

Trending on Xconomy